Virtus Investment Advisers’s AbCellera Biologics ABCL Stock Holding History

Virtus Investment Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$490K	Sell	62,442 -12,885	-17%	-$63K	0.11%	213
2026 Q1	$263K	Buy	75,327 +1,839	+3%	+$6.62K	0.07%	304
2025 Q4	$251K	Buy	73,488 +37,365	+103%	+$167K	0.07%	327
2025 Q3	$182K	Buy	36,123 +6,271	+21%	+$27.6K	0.05%	269
2025 Q2	$102K	Sell	29,852 -25,793	-46%	-$64.2K	0.03%	327
2025 Q1	$124K	Buy	+55,645	New	+$160K	0.03%	387

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Virtus Investment Advisers's ABCL Position: Q2 2026 in Review

Virtus Investment Advisers reduced its AbCellera Biologics (ABCL) stake by 17% in Q2 2026, selling an estimated $63K and leaving 62,442 shares worth $490K. The position accounts for 0.11% of the portfolio, ranked #213.

Virtus Investment Advisers first reported a position in ABCL in Q1 2025 and has held it in 6 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Virtus Investment Advisers held 62,442 shares of AbCellera Biologics worth $490K as of Q2 2026.
Virtus Investment Advisers sold 12,885 AbCellera Biologics shares in Q2 2026, an estimated $63K.
AbCellera Biologics made up 0.11% of Virtus Investment Advisers's portfolio in Q2 2026, its #213 holding.
Virtus Investment Advisers first reported a position in AbCellera Biologics in Q1 2025 and has held it in 6 quarters since.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.